The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells

Leukemia Research

Volumn 20, Issue 6, 1996, Pages 473-480

  Rowley, Peter T ^a   Keng, Peter C ^a   Kosciolek, Barbara A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Antisense; Apoptosis; bcr abl; Chronic myeloid leukemia; DNA synthesis; K562 cells

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; BROXURIDINE; DNA NUCLEOTIDYLEXOTRANSFERASE; IODIDE; PROPIDIUM IODIDE; THYMIDINE; TRITIUM;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA SYNTHESIS; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL;

EID: 0030176135     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(95)00172-7     Document Type: Article

References (40)

1. 1. Rowley J. D. (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290.
2. 2. Groffen J., Stephenson J. R., Heisterkamp N., Klein A. de, Bartram C. R. & Grosveld G. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93.
3. 3. Gale R. P. & Canaani E. (1984) An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc. natn. Acad. Sci. USA 81, 5648.
4. 4. Heisterkamp N., Stam K., Groffen J., Klein A. de & Grosveld G. (1985) Structural organization of the bcr gene and its role in the Ph′ translocation. Nature 315, 758.
5. 5. Grosveld G., Verwoerd T., Agthoven T. van, Klein A. de, Ramachandran K. L., Heisterkamp N., Stam K. & Groffen J. (1986) The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol. Cell Biol. 6, 607.
6. 6. Ben-Neriah Y., Daley G. Q., Mes-Masson A. M., Witte O. N. & Baltimore D. (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233, 212.
7. 7. Shtivelman E., Lifshitz B., Gale R. P., Roe B. A. & Canaani E. (1986) Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 47, 277.
8. c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc. natn. Acad. Sci. USA 83, 9768.
9. 9. Stryckmans P., Debusscher L. & Socquet M. (1976) Regulation of bone marrow myeloblast proliferation in chronic myeloid leukemia. Cancer Res. 36, 3034.
10. 10. Holdrinet R. S. G., Pennings A., Egmond J. van, Wessels J. M. C. & Haanen C. (1983) DNA-flow cytometry of blood and bone marrow in chronic myelogenous leukemia. Acta Haematol. 69, 98.
11. 11. Andreeff M. (1986) Cell kinetics of leukemia. Semin. Hematol. 23, 300.
12. 12. Strife A. & Clarkson B. (1988) Biology of chronic myelogenous leukemia: is discordant maturation the primary defect? Semin. Hematol. 25, 1.
13. 13. Wang Z., Gao X. Z. & Preisler H. D. (1989) Studies of the proliferation and differentiation of immature myeloid cells in vitro II. Acute myelogenous leukemia. Am. J. Hematol. 30, 82.
14. 14. Laneuville P., Timm M. & Hudson A. T. (1994) Bcr/abl expression in 32D c13(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res. 54, 1360.
15. 15. Evans C. A., Owen-Lynch P. J., Whetton A. D. & Dive C. (1993) Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res. 53, 1735.
16. 16. Bedi A., Zehnbauer B. A., Barber J. P., Sharkis S. J. & Jones R. J. (1994) Inhibition of apoptosis by bcr-abl in chronic myeloid leukemia. Blood 83, 2038.
17. 17. Smetsers T. F. C. M., Skorski T., Locht L. T. F. van de, Wessels H. M. C., Pennings A. H. M., Witte T. de, Calabretta B. & Mensink E. J. B. M. (1994) Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 8, 129.
18. 18. McGahon A., Bissonnette R., Schmitt M., Cotter K. M., Green D. R. & Cotter T. G. (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83, 1179.
19. 19. Lozzio C. B. & Lozzio B. B. (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45, 321.
20. 20. Nelson P. S., Frye R. A. & Liu E. (1989) Bifunctional oligonucleotide probes synthesized using a novel CPG support are able to detect single base pair mutations. Nucl. Acids Res. 17, 7187.
21. 21. Dolbeare F., Gratzner H., Pallavicini M. G. & Gray J. W. (1983) Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc. natn. Acad. Sci. USA 80, 5573.
22. 22. Gorczyca W., Gong J. & Darzynkiewicz Z. (1993) Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 53, 1945.
23. 23. Gorczyca W., Bigman K., Mittelman A., Ahmed T., Gong J., Melamed M. R. & Darzynkiewicz Z. (1993) Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 7, 659.
24. 24. Hotz M. A., Gong J., Traganos F. & Darzynkiewicz Z. (1994) Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry 15, 237.
25. 3H]thymidine incorporation by 'control' oligonucleotides. Antisense Res. Devel. 2, 325.
26. 26. Pegoraro L., Matera L., Ritz J., Levis A., Palumbo A. & Biagini G. (1983) Establishment of a Phl-positive human cell line (BV173). J. natn. Cancer Inst. 70, 447.
27. 27. Kirkland M. A., O'Brien S. G. & Goldman J. M. (1994) Antisense therapeutics in haematological malignancies. Br. J. Haematol. 87, 447.
28. bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucl. Acids Res. 22, 2150.
29. 29. Bergan R. C., Kyle E., Connell Y. & Neckers L. (1995) Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res. Devel. 5, 33.
30. 30. Gao W. Y., Fu-Sheng H., Storm C., Egan W. & Cheng Y. C. (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Molec. Pharmacol. 41, 223.
31. 31. Giles R. V. & Tidd D. M. (1992) Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides. Anticancer Drug Des. 7, 37.
32. 32. Korsmeyer S. J. (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80, 879.
33. 33. Delia D., Aiello A., Soligo D., Fontanella E., Melani C., Pezzella F., Pierotti M. S. & Delia Porta G. (1992) bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79, 1291.
34. 34. Bi S., Lanza F. & Goldman J. M. (1994) The involvement of 'tumor suppressor' p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res. 54, 582.
35. 35. Ahuja H., Bar-Eli M., Advani S. H., Benchimol S. & Cline M. J. (1989) Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc. natn. Acad. Sci. USA 86, 6783.
36. 36. Kelman Z., Prokocimer M., Peller S., Kahn Y., Rechavi G., Manor Y., Cohen A. & Rotter V. (1989) Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 74, 2318.
37. 37. Mashal R., Shaltrid M., Talpaz M., Kantarjian H., Smith L., Beran M., Cork A., Trujillo J., Gutterman J. & Deisseroth A. (1990) Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 75, 180.
38. 38. Feinstein E., Cimino G., Gale R. P., Alimena G., Berthier R., Kishi K., Goldman J., Zaccaria A., Berrebi A. & Canaani E. (1991) p53 in chronic myelogenous leukemia in acute phase. Proc. natn. Acad. Sci. USA 88, 6293.
39. 39. Bi S., Lanza F. & Goldman J. M. (1993) The abnormal p53 proteins expressed in CML lines are non-functional. Leukemia 7, 1840.
40. 40. Law J. C., Ritke M. K., Yalowich J. C., Leder G. H. & Ferrell R. E. (1993) Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leukemia Res. 17, 1045.